Cigna earnings beat by $0.04, revenue topped estimates
NOVA LIMA, Brazil - Afya Limited (NASDAQ:AFYA), a Brazilian medical education group with a market capitalization of $1.59 billion, announced Tuesday that all resolutions proposed at its Annual General Meeting were approved by shareholders. The meeting resulted in the approval of the company’s financial statements for the fiscal year ended December 31, 2024, according to a press release statement.
Shareholders also approved the reappointment of four independent directors to Afya’s board, each to serve a two-year term effective immediately. The reappointed directors include João Paulo Seibel de Faria, Vanessa Claro Lopes, Miguel Filisbino Pereira de Paula, and Marcelo Ken Suhara.
Afya describes itself as a medical education provider in Brazil that offers services spanning from medical school education through continuing medical education and practice solutions for physicians throughout their careers.
The company’s shares are listed on the Nasdaq exchange under the ticker symbol AFYA. The Annual General Meeting was held following a notice dated June 9, 2025, which outlined the five resolutions that were subsequently passed.
In other recent news, Afya Limited has reported its first-quarter 2025 results, revealing that its medical school intake numbers have surpassed expectations. This led UBS to raise its price target for the company from $17.50 to $19.50, while maintaining a Neutral rating on the stock. UBS highlighted the potential for continued growth due to higher enrollment and integration at Unidom, although it noted challenges such as increased participation in Brazil’s FIES student loan program and a new tax regime as potential headwinds. Additionally, Afya has changed its independent registered public accounting firm, as disclosed in a recent SEC filing. The filing did not specify the new firm’s name or the reason for the change but is part of the company’s regular financial oversight. Afya also submitted its unaudited interim condensed consolidated financial statements for the period ending March 31, 2025, to the SEC. This filing, while not disclosing specific figures, is crucial for investor transparency and regulatory compliance. The company continues to meet its reporting obligations under the Securities Exchange Act of 1934, with CEO Virgilio Deloy Capobianco Gibbon signing the documents.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.